An outcome model approach to transporting a randomized controlled trial results to a target population

Abstract

ACKNOWLEDGMENTSWe thank the NAVIGATOR steering committee and investigators for access to the NAVIGATOR data Affiliations: AbstractParticipants enrolled into randomized controlled trials (RCTs) often do not reflect real-world populations. Previous research in how best to translate RCT results to target populations has focused on weighting RCT data to look like the target data. Simulation work, however, has suggested that an outcome model approach may be preferable. Here we describe such an approach using source data from the 2x2 factorial NAVIGATOR trial which evaluated the impact of valsartan and nateglinide on cardiovascular outcomes and new-onset diabetes in a "pre-diabetic" population. Our target data consisted of people with "pre-diabetes" serviced at our institution. We used Random Survival Forests to develop separate outcome models for each of the 4 treatments, estimating the 5-year risk difference for progression to diabetes and estimated the treatment effect in our local patient populations, as well as sub-populations, and the results compared to the traditional weighting approach. Our models suggested that the treatment effect for valsartan in our patient population was the same as in the trial, whereas for nateglinide treatment effect was stronger than observed in the original trial. Our effect estimates were more efficient than the weighting approach.

The present and future scope of real‐world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?

“…Beyond the intense discussion on what exactly ML means and its pros and cons compared to “classical” statistical modelling methods, it is worth noting that the use of ML algorithms in medicine has received a wider attention following the demonstration of a performance similar to human clinical decision in the field of diabetes medicine, namely the diagnosis of diabetic retinopathy . ML models have been applied in diabetes to define clusters of diabetes phenotypes; predict kidney disease, hypoglycaemia, or glucose control; identify risk factors for CVD and death in diabetes; develop prediction models for complications; or transport RCT data to a target population …”

Machine learning in pharmacometrics: Opportunities and challenges

“…This method was further developed to harness used ML global optimization algorithms, including: simulated annealing and nested simulated annealing; Metropolis-Hasting; and GA. 144,145 Additionally, new approaches for translating the information gained from randomized controlled trials to specific target populations using RF are being developed. 146 10 Previous work in our group demonstrated a novel approach to integrate pharmacogenomics data in PK/PD modelling using information theoretic approaches. 148 This method was used to simultaneously evaluate gene-environmental interactions using PK/PD, clinical outcomes and genome-wide pharmacogenetic data.…”

“…This method was further developed to harness used ML global optimization algorithms, including: simulated annealing and nested simulated annealing; Metropolis–Hasting; and GA 144,145 . Additionally, new approaches for translating the information gained from randomized controlled trials to specific target populations using RF are being developed 146 …”

Application of Surgical Decision Model for Patients With Childhood Cataract: A Study Based on Real World Data

“…Real-world data (RWD) can probably solve the executive risks of RWCSs. RWD is from patient medical chart reviews and registries rather than conventional randomized controlled trials (Elliott et al, 2016;Goldstein et al, 2019), which has been acknowledged as more favorable and valuable for guiding medical decisions (Goulooze et al, 2020). Published study has achieved a surgical decision model for a rare disease, childhood cataract (CC) (Lin D. et al, 2019).…”